封面
市场调查报告书
商品编码
1751220

美国兽医肿瘤市场规模、份额、趋势分析报告:按动物、治疗方法、癌症类型和细分市场划分,预测(2025-2030 年)

U.S. Veterinary Oncology Market Size, Share & Trends Analysis Report By Animal (Canine, Feline, Equine), By Therapy (Radiotherapy, Surgery, Chemotherapy, Immunotherapy), By Cancer Type, And Segment Forecasts, 2025 - 2030

出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10个工作天内

价格

美国兽医肿瘤市场的成长与趋势:

根据 Grand View Research, Inc. 的最新报告,美国兽医肿瘤市场规模预计到 2030 年将达到 14.8 亿美元,2025 年至 2030 年期间的复合年增长率为 12.58%。

推动市场成长的主要因素包括宠物癌症发生率的上升、宠物饲主在宠物身上花费更多资金的意愿,以及研究人员将狗作为临床试验的模型。此外,猫科动物癌症发病率的上升以及人们对宠物健康的日益关注导致的宠物拥有量的增加,预计也将刺激市场成长。此外,各公司正在采取併购、研究协议、联盟、伙伴关係关係、地理扩张和产品开发等策略,以巩固其市场地位。

例如,2020年11月,VirusVac宣布核准核准用于治疗犬隻淋巴瘤。因此,预计预测期内市场竞争将更加激烈。伴侣动物癌症盛行率的不断上升预计将推动对有效治疗方案的需求。

对于犬类来说,骨癌是一种高度侵袭性疾病,其治癒性治疗包括手术切除肿瘤,然后进行化疗,以降低癌细胞转移到其他部位(尤其是肺部)的风险。据报道,黄金猎犬的癌症发生率高于其他犬种。黄金猎犬是美国最受欢迎的犬种之一,人们对宠物健康的日益关注也推动了该市场的成长。临床试验是兽医肿瘤学的一个重要方面。宠物外科临床研究的加速发展将进一步推动市场的成长。

例如,2019年5月,奥勒冈州立大学进行的一项研究发现,完全切除肿瘤的狗的癌症復发风险降低了60%。在美国,随着饲养宠物的人数增加,人们越来越关注动物健康。美国举办各种活动来传播宠物健康意识,例如全国宠物週。人们认为动物将COVID-19传播给个人的风险很小。 FDA担心COVID-19大流行可能会影响正在进行的开发新药兽药研发研究。因此,在2020年4月发布了指南,以减轻疫情对开发新药的潜在影响。

美国兽医肿瘤市场报告重点

  • 放射科领域预计将占据市场主导地位。政府加大倡议建立新的兽医放射中心以及放射技术的进步等因素预计将推动该领域的成长。
  • 由于专注于进行该领域临床试验的兽医诊所数量不断增加,预计免疫疗法领域将在 2025 年至 2030 年间实现最快的复合年增长率。
  • 预计到 2030 年,化疗将成为第二大治疗领域。根据癌症兽医中心的数据,用化疗治疗的最常见犬和猫肿瘤包括骨癌、淋巴瘤、血管肉瘤、肥大细胞瘤、膀胱肿瘤和乳房肿瘤。
  • 犬类市场占据了 2024 年最大的收益占有率。犬类癌症的高发生率以及该领域持续的产品创新促进了该领域的成长。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国兽医肿瘤市场变数、趋势与范围

  • 市场展望
    • 母市场展望
    • 相关/支持市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场机会分析
    • 市场问题分析
  • 美国兽医肿瘤市场分析工具
    • 波特分析
    • PESTEL分析
  • COVID-19分析
  • 以主要物种估算的宠物数量

第四章美国兽医肿瘤市场:动物估计与趋势分析

  • 细分仪表板
  • 美国兽医肿瘤市场变化分析
  • 美国兽医肿瘤市场规模及趋势分析(依动物种类,2018-2030)
  • 猫科

第五章美国兽医肿瘤市场:治疗方法估计与趋势分析

  • 细分仪表板
  • 美国兽医肿瘤市场变化分析
  • 2018-2030 年美国兽医肿瘤市场规模及治疗方法趋势分析
  • 放射线治疗
    • 立体定位放射治疗
    • 常规放射线治疗
  • 外科手术
  • 化疗
  • 免疫疗法
  • 其他治疗方法

第六章美国兽医肿瘤市场:癌症类型估计与趋势分析

  • 细分仪表板
  • 美国兽医肿瘤市场变化分析
  • 2018-2030 年美国兽医肿瘤市场规模及趋势分析(依癌症类型)
  • 皮肤癌
  • 淋巴瘤
  • 肉瘤
  • 其他的

第七章 竞争态势

  • 市场参与企业分类
  • 企业市场分析/热图分析
  • 2023 年企业市场占有率评估分析
  • 战略地图
    • 合併与收购
    • 伙伴关係和合作
    • 其他的
  • 公司简介
    • Elanco
    • Boehringer Ingelheim International GmbH.
    • Zoetis
    • PetCure Oncology
    • Accuray Incorporated
    • Varian Medical Systems, Inc.
    • Elekta AB.
    • Karyopharm Therapeutics, Inc.
    • Virbac.
    • Merck &Co., Inc.
    • Dechra Pharmaceuticals PLC
    • NovaVive Inc.
    • Ardent Animal Health, LLC(A BreakthrU Company).

第八章 重点

Product Code: GVR-4-68039-370-4

U.S. Veterinary Oncology Market Growth & Trends:

The U.S. veterinary oncology market size is estimated to reach USD 1.48 billion by 2030, expanding at a CAGR of 12.58% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of cancer in pets, willingness to spend on them by pet owners, and use of canines as a model for clinical trials by researchers are the key contributing factor toward the market growth. In addition, a rise in the incidence of cancer in the feline population and rising pet ownership resulting in the increased focus on pet health is further expected to spur the growth. Moreover, companies are increasingly adopting strategies, such as M&As, research agreements, collaboration, partnerships, geographic expansion, and product development to enhance their market position.

For instance, in November 2020, Virbac publicized the approval of Stelfonta, a novel intratumoral injection treatment for canine mast cell tumors. In addition, Elanco purchased Aratana Therapeutics for its pet products pipeline. The company also had an agreement to create rabacfosadine (Tanovea), a drug from VetDC. In addition, in July 2021, Elanco proclaimed that the FDA granted full approval of Tanovea for the lymphoma treatment in dogs. Hence, the market is expected to witness intense competition over the forecast period. The growing prevalence of cancer in companion animals is expected to propel the need for effective treatment options.

In canines, appendicular osteosarcoma is an extremely aggressive illness and curative-intent treatment comprises surgical resection of the tumor followed by chemotherapy to diminish the risk of tumor cells spreading to other areas, particularly the lungs. The golden retriever breed has been reported to have a high cancer prevalence compared to others. Golden Retriever is one of the favorite breeds in the U.S. and increasing concerns regarding the wellbeing of pets are contributing to the market growth. Clinical trials are a critical aspect of veterinary oncology. The accelerated number of clinical research involving surgical procedures in pets is further fueling the market growth.

For instance, in May 2019, Oregon State University conducted a research study stating that the risk of cancer recurrence reduced to 60% in dogs whose tumors were completely resected. With the growing number of pet parents in the U.S., animal health awareness is rising among people. In the U.S., various pet health awareness events are conducted to spread awareness, such as National Pet Week. The risk of animals spreading COVID-19 to individuals is considered to be little. The FDA is alert that the COVID-19 pandemic may influence the ongoing studies being conducted to provision new animal drug development. Thereby, guidelines were issued in April 2020 to help diminish the potential impact of the pandemic on new animal drug development.

U.S. Veterinary Oncology Market Report Highlights:

  • The radiology segment is expected to dominate the market. Factors, such as increasing government initiatives for the establishment of new veterinary radiation centers and advancements in radiation technology, are expected to boost the segment growth
  • The immunotherapy segment is estimated to register the fastest CAGR from 2025 to 2030 owing to the growing number of veterinary centers focused on carrying out clinical trials in immunotherapy areas
  • Chemotherapy is estimated to be the second-largest therapy segment by 2030. According to the Cancer Veterinary Center, the most common canine & feline tumors treated with chemotherapy are osteosarcomas, lymphomas, hemangiosarcoma, mast cell tumors, bladder tumors, mammary gland tumors, etc.
  • The canine segment accounted for the largest revenue share in 2024. The high incidence of cancer in canines and ongoing product innovations in this domain contributed to the segment growth

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Scope
    • 1.1.2. Estimates And Forecast Timeline
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis
    • 1.6.2. Global Market: CAGR Calculation
  • 1.7. Research Scope and Assumptions
    • 1.7.1. List of Secondary Sources
    • 1.7.2. List of Primary Sources
    • 1.7.3. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Veterinary Oncology Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Drivers Analysis
      • 3.2.1.1. Increasing Prevalence of Cancer in Pets
      • 3.2.1.2. Increasing R&D In Pet Cancer Therapy
      • 3.2.1.3. Growing Focus On Animal Safety
      • 3.2.1.4. Growing Uptake Of Pet Insurance
      • 3.2.1.5. Technological Advancements In Pet Cancer Treatment
      • 3.2.1.6. Increase In Pet Population
    • 3.2.2. Market Restraints Analysis
      • 3.2.2.1. High cost of treatment
      • 3.2.2.2. Adverse effects associated with therapies
      • 3.2.2.3. Limited Clinical Evidence
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenges Analysis
  • 3.3. U.S. Veterinary Oncology Market Analysis Tools
    • 3.3.1. Porter's Analysis
      • 3.3.1.1. Bargaining power of the suppliers
      • 3.3.1.2. Bargaining power of the buyers
      • 3.3.1.3. Threats of substitution
      • 3.3.1.4. Threats from new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and Social Landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental Landscape
      • 3.3.2.5. Legal landscape
  • 3.4. Covid-19 Analysis
  • 3.5. Estimated pet population, by key species

Chapter 4. U.S. Veterinary Oncology Market: Animal Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Veterinary Oncology Market Movement Analysis
  • 4.3. U.S. Veterinary Oncology Market Size & Trend Analysis, by Animal, 2018 to 2030 (USD Million)
  • 4.4. Canine
    • 4.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5. Feline
    • 4.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.6. Equine
    • 4.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Veterinary Oncology Market: Therapy Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Veterinary Oncology Market Movement Analysis
  • 5.3. U.S. Veterinary Oncology Market Size & Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
  • 5.4. Radiotherapy
    • 5.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. Stereotactic Radiation Therapy
      • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.4.2.2. LINAC
        • 5.4.2.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.4.2.3. Other Type
        • 5.4.2.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Conventional Radiation Therapy
      • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5. Surgery
    • 5.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6. Chemotherapy
    • 5.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.7. Immunotherapy
    • 5.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8. Other Therapies
    • 5.8.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Veterinary Oncology Market: Cancer Type Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Veterinary Oncology Market Movement Analysis
  • 6.3. U.S. Veterinary Oncology Market Size & Trend Analysis, by Cancer Type, 2018 to 2030 (USD Million)
  • 6.4. Skin Cancer
    • 6.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5. Lymphomas
    • 6.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6. Sarcomas
    • 6.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Market Participant Categorization
  • 7.2. Company Market Position Analysis/ Heat Map Analysis
  • 7.3. Estimated Company Market Share Analysis, 2023
  • 7.4. Strategy Mapping
    • 7.4.1. Mergers & Acquisitions
    • 7.4.2. Partnerships & Collaborations
    • 7.4.3. Others
  • 7.5. Company Profiles
    • 7.5.1. Elanco
      • 7.5.1.1. Participant's Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Boehringer Ingelheim International GmbH.
      • 7.5.2.1. Participant's Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Zoetis
      • 7.5.3.1. Participant's Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. PetCure Oncology
      • 7.5.4.1. Participant's Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Accuray Incorporated
      • 7.5.5.1. Participant's Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Varian Medical Systems, Inc.
      • 7.5.6.1. Participant's Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Elekta AB.
      • 7.5.7.1. Participant's Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Karyopharm Therapeutics, Inc.
      • 7.5.8.1. Participant's Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Virbac.
      • 7.5.9.1. Participant's Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Merck & Co., Inc.
      • 7.5.10.1. Participant's Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives
    • 7.5.11. Dechra Pharmaceuticals PLC
      • 7.5.11.1. Participant's Overview
      • 7.5.11.2. Financial Performance
      • 7.5.11.3. Product Benchmarking
      • 7.5.11.4. Strategic Initiatives
    • 7.5.12. NovaVive Inc.
      • 7.5.12.1. Participant's Overview
      • 7.5.12.2. Financial Performance
      • 7.5.12.3. Product Benchmarking
      • 7.5.12.4. Strategic Initiatives
    • 7.5.13. Ardent Animal Health, LLC (A BreakthrU Company).
      • 7.5.13.1. Participant's Overview
      • 7.5.13.2. Financial Performance
      • 7.5.13.3. Product Benchmarking
      • 7.5.13.4. Strategic Initiatives

Chapter 8. Key Takeaways

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Veterinary Oncology Market, by Animal, 2018 - 2030 (USD Million)
  • Table 4 U.S. Veterinary Oncology Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 5 U.S. Veterinary Oncology Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 6 Company Overview
  • Table 7 Service Benchmarking
  • Table 8 Financial Performance
  • Table 9 Strategic Initiatives

List of Figures

  • Fig. 1 U.S. Veterinary Oncology Market Segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Data Analysis Models
  • Fig. 6 Market Formulation And Validation
  • Fig. 7 Data Validating & Publishing
  • Fig. 8 General methodology for a commodity flow analysis of the U.S. Veterinary Oncology Market
  • Fig. 9 Commodity flow analysis
  • Fig. 10 Parent market analysis
  • Fig. 11 Market Snapshot
  • Fig. 12 Segment snapshot
  • Fig. 13 Segment snapshot
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Parent market value, 2024 (USD Billion)
  • Fig. 16 Ancillary market outlook, 2024
  • Fig. 17 U.S. Veterinary Oncology Market Dynamics
  • Fig. 18 Estimated animal population, 2018-2024 by key species and key countries
  • Fig. 19 U.S. Veterinary Oncology Market: PORTER's analysis
  • Fig. 20 U.S. Veterinary Oncology Market: PESTEL analysis
  • Fig. 21 U.S. Veterinary Oncology Market by Animal: Key Takeaways
  • Fig. 22 U.S. Veterinary Oncology Market by Animal, 2024 & 2030
  • Fig. 23 Canine market, 2018 - 2030 (USD Million)
  • Fig. 24 Feline market, 2018 - 2030 (USD Million)
  • Fig. 25 Equine market, 2018 - 2030 (USD Million)
  • Fig. 26 Horses market, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. Veterinary Oncology Market by Therapy: Key Takeaways
  • Fig. 28 U.S. Veterinary Oncology Market by Therapy, Market Share, 2024 & 2030
  • Fig. 29 Radiotherapy market, 2018 - 2030 (USD Million)
  • Fig. 30 Stereotactic Radiation Therapy market, 2018 - 2030 (USD Million)
  • Fig. 31 LINAC market, 2018 - 2030 (USD Million)
  • Fig. 32 Other Stereotactic Radiation Therapy market, 2018 - 2030 (USD Million)
  • Fig. 33 Conventional Radiation Therapy market, 2018 - 2030 (USD Million)
  • Fig. 34 Surgery market, 2018 - 2030 (USD Million)
  • Fig. 35 Chemotherapy market, 2018 - 2030 (USD Million)
  • Fig. 36 Immunotherapy market, 2018 - 2030 (USD Million)
  • Fig. 37 Other therapies market, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. Veterinary Oncology Market by Cancer Type: Key Takeaways
  • Fig. 39 U.S. Veterinary Oncology Market by Cancer Type, Market Share, 2024 & 2030
  • Fig. 40 Skin Cancers market, 2018 - 2030 (USD Million)
  • Fig. 41 Lymphomas market, 2018 - 2030 (USD Million)
  • Fig. 42 Sarcomas market, 2018 - 2030 (USD Million)
  • Fig. 43 Other market, 2018 - 2030 (USD Million)
  • Fig. 44 Market Participant Categorization
  • Fig. 45 Heat map analysis
  • Fig. 46 Strategic Framework